Loading stock data…
Arcus Biosciences (RCUS)
$29.06-0.60 (-2.02%)
Market ClosedLast close Sep 8
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Arcus Biosciences, Inc. in the Healthcare sector is trading at $29.06 with a market capitalization of $3.0B. Wall Street consensus targets $38.75 (12 analysts), implying a +33.3% move over the next 12 months. The stock is currently near its 52-week high of $31.73, remaining 17.8% above its 200-day moving average. On fundamentals, Piotroski 0/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +33.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $17.00M↓ | $33.00M↑ | $26.00M↓ | $160.00M↑ | $28.00M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$134.00M↓ | -$114.00M↑ | -$142.00M↓ | -$8.00M↑ | -$122.00M |
| Net Income | -$128.00M↓ | -$106.00M↑ | -$135.00M | $0↑ | -$112.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney ca...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.96B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-70.42%
Volume
Today's trading volume
1.36M
Recent News
Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard?
On July 22, Arcus Biosciences, Inc. (NYSE:RCUS) and Summit Therapeutics Inc. (NASDAQ:SMMT) announced a major clinical trial collaboration to combine Arcus’s casdatifan (an investigational HIF-2α inhibitor) with Summit’s ivonescimab (an investigational PD-1/VEGF bispecific antibody). The study aims to evaluate the safety and efficacy of this combination in clear cell renal cell carcinoma (ccRCC), including first-line […]
Arcus Biosciences (RCUS) Q2 2026 Earnings Call Transcript
CEO Rosen targets casdatifan as $5B to $10B drug with no frontline competition.
Arcus Biosciences' Casdatifan Therapy Could be Launched in 2028, Morgan Stanley Says
Arcus Biosciences (RCUS) Casdatifan therapy for renal cell carcinoma could be launched in 2028 and p
Arcus Biosciences Q2 Earnings Call Highlights
Arcus Biosciences (NYSE:RCUS) outlined plans to expand development of its casdatifan cancer program across multiple lines of clear cell renal cell carcinoma, or ccRCC, while reporting second-quarter financial results and updates on its pancreatic cancer and immunology pipelines. Chief Executive Off
Arcus Biosciences (RCUS) Stock Gets Fair Value Bump After Casdatifan Optimism
The fair value estimate for Arcus Biosciences has shifted from US$35.75 to US$38.00, signaling a modest reset in where analysts think the stock could reasonably trade. That move tracks with recent updates that balance enthusiasm around the kidney cancer franchise, especially casdatifan, against questions about how quickly those programs can translate into durable commercial performance. As you read on, you will see how this evolving narrative might shape your view of Arcus Biosciences over...